Join Growin Stock Community!

Macrogenics, inc.MGNX.US Overview

US StockHealthcare
(No presentation for MGNX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MGNX AI Insights

MGNX Overall Performance

MGNX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MGNX Recent Performance

-1.76%

Macrogenics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

MGNX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MGNX Key Information

MGNX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MGNX Profile

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Price of MGNX

MGNX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MGNX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.20
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.99
PB Ratio
1.87
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
75.41%
Net Margin
-59.46%
Revenue Growth (YoY)
-9.70%
Profit Growth (YoY)
-28.37%
3-Year Revenue Growth
20.40%
3-Year Profit Growth
16.65%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.20
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.99
PB Ratio
1.87
Price-to-FCF
-
Gross Margin
75.41%
Net Margin
-59.46%
Revenue Growth (YoY)
-9.70%
Profit Growth (YoY)
-28.37%
3-Year Revenue Growth
20.40%
3-Year Profit Growth
16.65%

  • When is MGNX's latest earnings report released?

    The most recent financial report for Macrogenics, inc. (MGNX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MGNX's short-term business performance and financial health. For the latest updates on MGNX's earnings releases, visit this page regularly.

  • What is the operating profit of MGNX?

    According to the latest financial report, Macrogenics, inc. (MGNX) reported an Operating Profit of 18.64M with an Operating Margin of 25.59% this period, representing a decline of 65.61% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is MGNX's revenue growth?

    In the latest financial report, Macrogenics, inc. (MGNX) announced revenue of 72.84M, with a Year-Over-Year growth rate of -34.21%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does MGNX have?

    As of the end of the reporting period, Macrogenics, inc. (MGNX) had total debt of 107.27M, with a debt ratio of 0.4. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MGNX have?

    At the end of the period, Macrogenics, inc. (MGNX) held Total Cash and Cash Equivalents of 80.13M, accounting for 0.3 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does MGNX go with three margins increasing?

    In the latest report, Macrogenics, inc. (MGNX) achieved the “three margins increasing” benchmark, with a gross margin of 84.1%%, operating margin of 25.59%%, and net margin of 23.1%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MGNX's profit trajectory and future growth potential.

  • Is MGNX's EPS continuing to grow?

    According to the past four quarterly reports, Macrogenics, inc. (MGNX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.27. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MGNX?

    Macrogenics, inc. (MGNX)'s Free Cash Flow (FCF) for the period is -30.61M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 151.32% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MGNX?

    The latest valuation data shows Macrogenics, inc. (MGNX) has a Price-To-Earnings (PE) ratio of -1.23 and a Price/Earnings-To-Growth (PEG) ratio of -0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.